Seek Labs’ BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)

Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced successful mapping of the Respiratory Syncytial Virus (RSV) genome using its proprietary BioSeeker™ discovery engine to address one of global health’s most persistent and costly viral threats. By pinpointing highly conserved genomic targets, this mapping accelerates development of a programmable CRISPR-based therapeutic on the company’s Programmable Target Ablation Platform (PTAP™). To date, only one antiviral drug has been approved to treat active RSV infection—used sparingly due to cost and significant adverse side effects—highlighting an urgent need for safe, scalable treatments. Seek Labs’ approach enables development of a single pan-RSV therapeutic candidate designed to treat both A and B subtypes.

RSV: An Urgent Global Health Threat

Each year, RSV causes an estimated 30 million infections globally and more than 100,000 deaths, placing a heavy, recurring burden on healthcare systems worldwide. Seasonal surges routinely overwhelm pediatric wards and intensive care units in North America, Europe, and Australia, among others. Seek Labs’ PTAP platform offers a fundamentally new approach to address this critical therapeutic gap, transforming the fight against RSV from limited treatment options to precise genomic targeting.

BioSeeker Pinpoints RSV’s Genomic Vulnerabilities

BioSeeker scanned over 290,000 publicly available RSV sequences, identifying a multiplexed set of high-potential, PTAP-compatible genomic targets in stable and conserved regions critical for RSV viral replication. These sites form a blueprint for a programmable, CRISPR-based “seek-and-destroy” therapeutic designed to precisely target RSV at its genetic core. This approach accelerates RSV therapeutic development and demonstrates the platform’s potential to rapidly address other high-priority viral threats.

Strategic Addition to the Global Disease Atlas

RSV now joins a growing roster of mapped, high-priority viruses in Seek Labs’ Global Disease Atlas, a continuously updated resource that is on track to map over 95% of the world’s most consequential viral pathogens. By building this strategic repository of high-impact targets, Seek Labs is equipping partners with tools to respond quickly and decisively to both endemic challenges like RSV and future emerging threats.

Call for Development Partners

Seek Labs is actively advancing development of an RSV-targeted therapeutic and invites qualified partners to join this vital effort. By combining BioSeeker’s precision target maps with the company’s cutting-edge Programmable Target Ablation Platform, Seek Labs offers partners an accelerated, de-risked path to advance a potential breakthrough RSV therapeutic and establish leadership in the next generation of programmable antivirals.

About Seek Labs

At Seek Labs, we don’t wait for change—we build it. We’re seeking the breakthroughs the world can’t wait for by developing programmable “seek and destroy” therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. Powered by our AI discovery engine, BioSeeker™, these platforms form a full-stack development engine—from target discovery to real-world deployment—designed to accelerate innovation and impact across global health.

Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah’s collaborative life sciences ecosystem. Together with our partners, we’re building faster, smarter solutions for the world’s most urgent health challenges.

Forward-Looking Statements and Regulatory Disclaimer

This press release includes forward-looking statements about Seek Labs’ technologies, development plans, and partnership opportunities. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ. The technologies described are investigational and have not been reviewed or approved by the FDA or any other regulatory authority for clinical or commercial use.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250707176242/en/